New oxazolidinone derivatives as antibacterial agents with improved activity

Bibliography

• National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004. Am J Infect Control 2004;32:470-85
   PubMedGoogle Scholar
• Goossens H. European status of resistance in nosocomial infections. Chemotherapy 2005;51(4):177-81
   PubMedGoogle Scholar
• Antimicrobial Resistance Prevention Initiative: Proceedings of an Expert Panel on Resistance. Am J Infect Control 2006;34(5 Suppl):A1-S79
   PubMedGoogle Scholar
• Jones RN, Fritsche TR, Sader HS, Ross JE. Zyvox Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diag Microbiol Infect Dis 2007;59:199-209
   PubMed Web of Science ®Google Scholar
• Anderegg TR, Sader HS, Fritsche TR, et al. Trends in linezolid susceptibility patterns: report from the 2002 – 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 2005;26:13-21
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8
   PubMed Web of Science ®Google Scholar
• Kelly S, Collins J, Davin M, et al. Linezolid resistance in coagulase-negative staphylococci. J Antimicrob Chemother 2006;58(4):898-9
   PubMedGoogle Scholar
• Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006;27:300-2
   PubMed Web of Science ®Google Scholar
• Potoski BA, Adams J, Clarke L. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 2006;43:165-71
   PubMed Web of Science ®Google Scholar
• Harris CR, Thorarensen A. Advances in the discovery of novel antibacterial agents during the year 2002. Curr Med Chem 2004;11:2213-43
   PubMedGoogle Scholar
• Bush K, MacielaGM, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr Opin Microbiol 2004;7:466-76
   PubMed Web of Science ®Google Scholar
• Phillips OA. Antibacterial agents: patent highlights January to June 2004. Curr Opin Invest Drugs 2004;5:799-808
   PubMedGoogle Scholar
• Gravestock MB. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Dev 2005;8:469-77
   PubMedGoogle Scholar
• Mukhtar TA, WrighT GD. Streptogramins, oxazolidinones and other inhibitors of bacterial protein synthesis. Chem Rev 2005;105(2):529-42
   PubMed Web of Science ®Google Scholar
• Hermann T. Drugs targeting the Ribosome. Curr Opin Struct Biol 2005;15:355-66
   PubMed Web of Science ®Google Scholar
• Tenson T, Mankin A. Antibiotics and the ribosome. Mol Microbiol 2006;59(6):1664-77
   PubMed Web of Science ®Google Scholar
• Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed 2003;42:2010-23
   PubMed Web of Science ®Google Scholar
• Hutchinson DK. Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem 2003;3:1021-42
   PubMed Web of Science ®Google Scholar
• Hutchinson DK. Recent advances in oxazolidinone antibacterial agent research. Expert Opin Ther Patents 2004;14:1309-28
   Web of Science ®Google Scholar
• Nilius AM. Have the oxazolidinones lived up to their billing. Future perspectives for this antebacterial class. Curr Opin Invest Drugs 2003;4:149-55
   PubMedGoogle Scholar
• Renslo AR, Luehr GW, Gordeev MF. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg Med Chem 2006;14:4227-40
   PubMed Web of Science ®Google Scholar
• Zappia G, Delle Monache G, Menendez P, et al. The contribution of oxazolidinone frame to the biological activity for pharmaceutical drugs and natural products. Mini Rev Med Chem 2007;7:389-409
   PubMedGoogle Scholar
• Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45
   PubMed Web of Science ®Google Scholar
• Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperozolid on translation reactions. Antimicrob Agents Chemother 1997;41:2132-6
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5
   PubMed Web of Science ®Google Scholar
• Woodford N. Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Micro Inf 2005;11(3):2-21 and references therein
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Waldon DJ, et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 2003;278:21972-9
   PubMed Web of Science ®Google Scholar
• Chiba K, Feenstra KL, Slatter JG, et al. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA; 1998
   Google Scholar
• Xu J, Golshani A, Aoki H, et al. Protected nucleoyide G2608 rRNA confers resistance to oxazolidinones in E. coli. Biochem Biophs Res Commun 2005;328:471-6
   PubMedGoogle Scholar
• Yeong WO, Weon BI, Jae KR, et al. Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring. Bioorg Med Chem 2004;12:5909-15
   PubMedGoogle Scholar
• Lee JG, Leem WB, Cho JH, et al. Novel oxazolidinone derivatives and process for the preparation thereof. WO200194342 (2001)
   Google Scholar
• Rhee JK, Im WB, Cho JH, et al. Novel oxazolidinone derivatives. WO2005058886 (2005)
   Google Scholar
• Gravestock MB, Hales NJ, Turner P. Antibacterial oxazolidinones. WO2004056816 (2004)
   Google Scholar
• Gravestock MB, Hales NJ, Reck F, Zhou F. Chemical compounds. WO2004048350 (2004)
   Google Scholar
• Carcanague DR, Gravestock MB. 3-[4-(6-{4,5-dihydroisoxazol-3-yl}pyridin-3-yl)-3phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents. WO2005116021 (2005)
   Google Scholar
• Gravestock MB, Reck F, Zhou F. 3-[4-{6-(substituted alkanoyl)} pyridin-3-yl)-3phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents. WO2005116022 (2005)
   Google Scholar
• Gravestock MB, Reck F, Zhou F. 3-{4-(pyridin-3-yl)phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents. WO2005116023 (2005)
   Google Scholar
• Gravestock MB, Carcanague DR. 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)-phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as MAO inhibitors fort he treatment bacterial infections. WO2005116024 (2005)
   Google Scholar
• Gravestock MB, Hales NJ, Carcanague DR. Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents. WO2004078753 (2004)
   Google Scholar
• Gravestock MB, Hales NJ. Antibacterial compounds. WO2004048370 (2004)
   Google Scholar
• Carcanague DR, Gravestock MB, Hales NJ, et al. Oxazolidinone and/or isoxazoline derivatives as antibacterial agents. WO2004048392 (2004)
   Google Scholar
• Akella SSVS, Mathiyazhagan K, Samuel MM, et al. New compounds as antibacterial agents. WO2005003087 (2005)
   Google Scholar
• Fukuda Y. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof. WO2005005398 (2005)
   Google Scholar
• Fukuda Y. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof. WO2005005420 (2005)
   Google Scholar
• Renslo AR, Gordeev MF, Patel DV, et al. Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues. WO2004089943 (2004)
   Google Scholar
• Hammond ML, Fukuda Y. Oxazolidinone antibiotics and derivatives thereof. WO2005005399 (2005)
   Google Scholar
• Hammond ML, Fukuda Y. Oxazolidinone antibiotics and derivatives thereof. WO2005005422 (2005)
   Google Scholar
• Gravestock MB, Hales NJ, Hauck SI. Antibacterial oxazolidinones. WO2004083206 (2004)
   Google Scholar
• Kang JH, Park CH, Kwon JS. A novel oxazolidinone derivative and manufacturing process thereof. WO2005042523 (2005)
   Google Scholar
• Cano M, Palomer A, Guglietta A. Oxazolidinone compounds and compositions and methods related thereof. WO2006010756 (2006)
   Google Scholar
• Mehta A, Rudra S, Rao AVS, et al. Oxazolidinone derivatives as antimicrobial. WO2004069816 (2004)
   Google Scholar
• Mehta A, Rudra S, Rao AVSR, et al. Oxazolidinone derivatives as antimicrobials. WO2004089944 (2004)
   Google Scholar
• Das B, Ahmed S, Yadav AS, et al. Oxazolidinone derivatives as antimicrobials. WO2006018682 (2006)
   Google Scholar
• Das B, Rudra S, Salman M, Rattan A. Oxazolidinone derivatives as antimicrobials. WO2006035283 (2006)
   Google Scholar
• Das B, Ahmed S, Yadav AS, et al. Oxazolidinone derivatives as antimicrobials. WO2006038100 (2006)
   Google Scholar
• Gurjar MK, Deshmukh MN, Arora SK, et al. Substituted oxazolidinone derivatives. WO2006040614 (2006)
   Google Scholar
• Mehta A, Das B, Rudra S, et al. Oxazolidinone derivatives as antimicrobials. WO2006043121 (2006)
   Google Scholar
• Das B, Yadav AS, Ahmed S, et al. Oxazolidinone derivatives as antimicrobials. WO2006051408 (2006)
   Google Scholar
• Das B, Rudra S, Sangita S, et al. Oxazolidinone derivatives as antimicrobials. WO2006109156 (2006)
   Google Scholar
• Salman M, Das B, Rudra S, et al. Oxazolidinone derivatives as antimicrobials. WO2005082899 (2005)
   Google Scholar
• Akella SSVS, Agrawal SK, Shinde AD, Samuel MM. Oxazole derivatives as antibacterial agents. WO2004113329 (2004)
   Google Scholar
• Mehta A, Rao AVSR, Rattan A. Oxazolidinone derivatives as antimicrobials. WO2004099199 (2004)
   Google Scholar
• Akella SSVS, Agrawal SK, Samuel MM. Oxazolidinone derivatives as antibacterial agents. WO2004101552 (2004)
   Google Scholar
• Gordeev MF, Josyula VPVN, Luehr GW, Jain R. Oxazolidinone amidoximes as antibacterial agents. WO2005082900 (2005)
   Google Scholar
• Barbachyn MR, Harris CR, Josyula VPVN. Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents. WO2005113520 (2005)
   Google Scholar
• Donovan CFJ, Josyula VPVN, Lall MS, Renslo AR. Thiazepine oxazolidinones as antibacterial agents. WO2006056875 (2006)
   Google Scholar
• Herradura PS, Josyula VPVN, Renslo AR. Diazepine oxazolidinones as antibacterial agents. WO2006056877 (2006)
   Google Scholar
• Gordeev MF, Josyula VPVN, Luehr GW. An oxindole oxazolidinone as antibacterial agents. WO2006106426 (2006)
   Google Scholar
• Gordeev MF, Josyula VPVN, Luehr GW. 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents. WO2006106427 (2006)
   Google Scholar
• Chupak LS, Kaneko T, Josyula VPVN, Jiano W. Oxazolidinone derivatives N-substituted by a tricyclic ring, for use as antibacterial agents. WO2004/069245 (2004)
   Google Scholar
• Chupak LS, Kaneko T, Josyula VPVN, et al. Antibacterial agents. WO2004/069832 (2004)
   Google Scholar
• Harris CR, Hester JBJ. N-(4-(piperazin-1-yl)-phenyl-2-oxazolidinone-5-carboxamide derivatives and related compounds as antibacterial agents. WO2004045616 (2004)
   Google Scholar
• Harris CR. N-aryl-2-oxazolidinone-5-carboxamide derivatives with antibacterial activity. WO2004087697 (2004)
   Google Scholar
• Deshpande PK, Sindkhedkar MD, Phansalkar MS, et al. Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy. WO2005054234 (2005)
   Google Scholar
• Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004;25:215-21
   PubMed Web of Science ®Google Scholar
• Ramsay RR, Gravestock MB. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev Med Chem 2003;3:129-36
   PubMedGoogle Scholar
• Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001;41:552-62
   PubMed Web of Science ®Google Scholar
• Amnet PW, Jamshed N, Horno JP. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am Fam Phys 2002;65:663-70
   PubMedGoogle Scholar
• Harrison WM, McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. J Clin Psychiatry 1989;50:64-5
   PubMedGoogle Scholar
• Naruganahalli KS, Shirumalla RK, Bansal V, et al. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats. Eu J Pharmacol 2006;545:167-72
   PubMedGoogle Scholar
• Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42:1578-83
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20
   PubMed Web of Science ®Google Scholar
• Isbister GK, Buckley NA. The pathophysiology of the serotonin toxicity in animal and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005;28:205-14
   PubMed Web of Science ®Google Scholar
• Reck F, Zhou F, Girardot M, et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005;48:499-506
   PubMed Web of Science ®Google Scholar